Celcuity Inc. (CELC): Price and Financial Metrics


Celcuity Inc. (CELC): $21.29

0.79 (+3.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CELC Stock Price Chart Interactive Chart >

Price chart for CELC

CELC Price/Volume Stats

Current price $21.29 52-week high $33.01
Prev. close $20.50 52-week low $5.00
Day low $20.99 Volume 66,500
Day high $22.37 Avg. volume 227,820
50-day MA $25.16 Dividend yield N/A
200-day MA $17.01 Market Cap 269.25M

Celcuity Inc. (CELC) Company Bio


Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.


CELC Latest News Stream


Event/Time News Detail
Loading, please wait...

CELC Latest Social Stream


Loading social stream, please wait...

View Full CELC Social Stream

Latest CELC News From Around the Web

Below are the latest news stories about Celcuity Inc that investors may wish to consider to help them evaluate CELC as an investment opportunity.

Analysts Say Celcuity Can Change Targeted Therapy Game

Rising incidences of cancer is leading to an increase in the scope of work for research and diagnostics companies. Notably, research firm Markets and Markets projects the global cancer diagnostics market to hit $26.6 billion by 2026, witnessing a CAGR of 11.5% between 2021 and 2026. Celcuity (CELC), a leading player in this field, is currently focused on developing its next-generation cancer diagnostic discovery platform — CELsignia. The platform evaluates tumor cells for aberrant signaling in entire key pathways to ascertain the best candidates for targeted therapies.

Chandrima Sanyal on TipRanks | July 28, 2021

Celcuity: Nipping The Oncogenic Bud

selvanegra/iStock via Getty Images Celcuity, Inc. (CELC) is a clinical-stage biotechnology company founded in 2012, to better diagnose the cellular abnormalities driving cancer, so that patients can receive the drugs best suited to alleviate their disease burden. Molecular tests cannot diagnose the cancer driver in 80% of cancer patients, which...

Avisol Capital Partners on Seeking Alpha | July 8, 2021

Celcuity to Participate in the William Blair Biotech Focus Conference

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its

Wallstreet:Online | July 8, 2021

Celcuity Inc.: Celcuity to Participate in the William Blair Biotech Focus Conference

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating p

FinanzNachrichten | July 8, 2021

Where Do Hedge Funds Stand On Celcuity Inc. (CELC)?

No summary available.

Insider Monkey | June 30, 2021

Read More 'CELC' Stories Here

CELC Price Returns

1-mo -12.49%
3-mo -23.03%
6-mo 45.82%
1-year 305.52%
3-year -11.77%
5-year N/A
YTD 132.42%
2020 -13.91%
2019 -55.65%
2018 26.60%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7693 seconds.